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Learning objectives 
 Increased skills in patient assessment, vulval examination, treatment of vulval disease. 
 Improved clinical outcomes for women through an increased understanding of basic and intermediate knowledge and skills of vulval 
disease according to national evidence base. 
 
Ethical issues 
 Clinicians managing vulval disease need to be sensitive and be willing to enquire about sexual problems associated. 
 All clinicians reviewing patients with vulval symptoms should have an understanding of the relevant conditions. Too often the most junior 
doctor in the gynaecology clinic reviews these patients 
 
Key content 
 Vulval disease is common in gynaecological practice. This article aims to enhance clinical skills in patient assessment, vulval 
examination and treatment of vulval disease specifically dermatological conditions.   
 Often simple measures can benefit the patient (e.g use of emollients), but many have complex disease and can present with more than 
one condition so careful assessment and individualised management is essential.  
 There are unmet training needs for some gynaecologists in the assessment and management of vulval skin disease so it is important to 
assess patients and refer difficult patients and non-responders onto a vulval service for a multidisciplinary opinion.  
 The management of common vulval skin disease will be covered, but vulvodynia the management of vulval intraepithelial neoplasia will 
not be discussed as they have been covered in previous TOG articles. 
 
History taking 
An accurate description of symptoms should be made as this can often point to a diagnosis when combined with the clinical examination. Table 
1 outlines some key questions to ask in the history and why. An assessment of the impact on function is always revealing (‘How do the 
symptoms affect you?’ or ‘What do you miss as a result of the problem?’) A psychosexual history should be explored if appropriate. Often 
referral of patients with a vulval problem might reveal sexual pain as the main complaint and secondary psychosexual problems such as 
avoidance, phobia of touch, loss of libido and vaginismus. The psychosexual impact of vulval skin disease has been covered in depth in 
previous TOG articles (1). 
 
Table 1 – vulval history taking  
Question Reasoning 
What are the key symptoms 
and how severe are they? 
What is the impact on the 
patient’s function? 
Important to be clear on the initial symptom. Itch can suggest skin disease or infection. 
Pain can be secondary to itching from skin damage. Pain as a primary symptom may 
indicate a pain syndrome. Improvement in function (including sex) is an important clinical 
outcome.  
How long has the woman been 
experiencing symptoms? 
Acute symptoms may indicate vulvovaginal thrush or contact dermatitis. Chronic 
symptoms may be due to lichen sclerosus or lichen planus.  
Are there any other symptoms? For example, vaginal discharge, vulval pain, other skin diseases. 
What treatments have been 
tried before? 
Inappropriate topical treatments can exacerbate symptoms and potentially cause an 
irritant reaction. The history should explore failed treatments e.g. topical steroid frequency 
and amount as under usage with these treatments is common 
How is the patient cleaning the 
vulval area? 
Many women feel unclean and can over-wash leading to skin damage and further 
irritation. 
Are there any possible contacts 
with irritants such as soaps, 
shampoos, urine, and scented 
vaginal wipes?  
These are potential irritants and can damage the skin potentially causing inflammation. 
Urine is a potent skin irritant. 
Are symptoms stress related? In lichen simplex, itching is classically worse at times of stress. 
Is there any systemic illness? For example, diabetes, renal failure, anaemia, autoimmune conditions (including family 
history of autoimmunity). 
Are there any other skin 
conditions present? 
For example, eczema or psoriasis (sometimes hidden as cracking behind the ears, a 
scaly scalp or umbilical erythema) 
 
Vulval examination 
A full vulval examination requires good lighting and each part of the vulva should be examined systematically including the mons pubis, inguinal 
folds, outer and inner labia (majora and minora), clitoris (body and hood), perineum, vestibule and anus (Fig 1). Hart’s line is the junction 
between the vestibule and the inner labia and marks change in epithelium type from mucosal type to stratified squamous. Ideally, digital and 
speculum examinations are important to rule out erosions, mucosal thickening, adhesions, and scarring as can be seen in conditions such as 
erosive lichen planus and lichen sclerosus (2).  
 
Vulval pathology may be a manifestation of a general skin condition and therefore a complete examination including hidden sites such as the 
umbilicus and natal cleft needs to be considered. Furthermore, examination of other non-keratinised or mucosal surfaces, including the oral 
cavity, eyes and mouth should be performed. This allows a more complete assessment of disease extent and diagnosis especially for diseases 
that are not solely restricted to the vulval region such as psoriasis, eczema, lichen sclerosus, pemphigus vulgaris, pemphigoid and erosive 
lichen planus. 
 
The terms used to describe vulval disease are largely synonymous with dermatology terminology. ‘Erythema’ refers to reddening of the skin, 
which may be poorly demarcated, as in eczema (Fig 2 demonstrates poorly defined erythema in the context of contact dermatitis) or well 
demarcated, as in psoriasis (Fig 3). The presence of erythema usually indicates an underlying inflammatory process. If present in association 
with pain, infection should be considered.  Whitening of the skin may occur in the presence of a normal epidermis such as in vitiligo, or in 
conjunction with epidermal change such as lichen sclerosus. ‘Lichenification’ is the term used to describe a leathery thickening of the skin with 
increased skin markings which occurs in response to persistent rubbing. The vulval region is often moist and scale is a less reliable sign than 
on other areas of the skin. It is most reliable on the mons pubis where scale may be a manifestation of psoriasis. On other sites such as the 
natal cleft, scale and lichenification may result in whiteness and splitting of the skin. This can make common conditions more difficult to 
diagnose (3). There are a number of terms that are used to describe specific lesions that may be found on the skin, including the vulval area 
(Table 2). 
 
 
 
 
 
 
 
 
 
Table 2: Terminology of lesions that may be seen in the vulval area 
Lesion 
terminology 
Description Example 
Fissure A thin ‘hairline’ crack in the skin surface due to excessive dryness Psoriasis and lichen sclerosus  
Excoriation Scratch mark, may be single or multiple As seen in any itchy skin conditions 
e.g. atopic eczema, lichen 
sclerosus 
Erosion A shallow denuded area due to loss of the epidermis (surface layer of 
skin) 
Erosive lichen planus 
Ulcer Full thickness loss of the epidermis (top layer of skin) +/- dermis Aphthous ulceration, 
Macule Flat area of colour change Vulval melanosis 
Ecchymosis (subcutaneous 
purpura) seen in lichen sclerosus 
Nodule Large palpable lesion greater than 0.5 cm in diameter Squamous cell carcinoma, Scabies 
Papule Small palpable lesion less than 0.5cm in diameter Genital warts 
Molluscum contagiosum 
Seborrhoeic keratosis 
Plaque A palpable flat lesion greater than 0.5 cm diameter. It may be elevated 
or may be a thickened area without being visibly raised above the skin 
surface 
Vulval Intraepithelial Neoplasia 
Squamous cell carcinoma 
Vesicle Small fluid filled blister less than 0.5cm diameter Bullous pemphigoid 
Lichenification An accentuation of skin markings commonly associated with 
thickening of epidermis usually caused by scratching or rubbing 
Lichen simplex 
 
Investigations 
 
Vaginal swabs  
These are indicated when the history suggests possible primary or secondary infection with bacterial, candida and viral infections. Infection is a 
common cause for loss of symptom control in inflammatory dermatoses. This may be a reason why lichen sclerosus appears initially well 
controlled with potent steroids and then flares. Occasionally, genital herpes can be a cause of vulval symptoms and a viral culture swab may be 
necessary.  
 
Vulval biopsy 
A vulval biopsy is usually indicated for 1), asymmetrical pigmented lesions, 2) persistently eroded areas, 3) indurated and suspicious ulcerated 
areas, 4) when there is poor response to treatment following the initial diagnosis. The site selected for biopsy should be tissue-representative of 
the lesion or area of abnormality. This is usually at the edge of the lesion and should also include some normal tissue. The most central area 
may be inflamed or necrotic, which may give minimal tissue diagnosis because of the inflammation present. An excisional biopsy can be 
problematic if the diagnosis is subsequently found to be cancer or VIN in that re-excision is often required. This can lead to further skin loss that 
might compromise function. Multiple mapping biopsies are indicated in cases of suspected multifocal disease. A 4mm Keyes punch biopsy is 
adequate and should ideally be carried out under local anaesthetic at the initial visit if possible. It can provide adequate tissue for histology but 
is not adequate if immunofluorescence is also required to exclude immunobullous disease when two biopsies may be needed. Inflammatory 
vulval lesions often have indistinct inflammatory pathology and a diagnosis should always be a clinic pathological correlation.   
 
Patch testing 
Patch testing by a dermatologist is indicated when allergic contact dermatitis is considered (see section on ‘Contact Dermatitis’). Common 
allergens include topical anaesthetics, fragrances, sodium lauryl sulphate and topical neomycin (4,5). Allergic contact dermatitis to the adhesive 
used in sanitary pads is relatively common and should be considered particularly if the fully keratinised epithelium is affected [6]. Since 
sensitisation can occur at any time it is a further reason why symptoms initially well controlled with topical therapies can flare. Clinical history is 
very important to determine potential sensitising agents which can then be applied to the skin during the patch testing process. 
 
The multidisciplinary team 
Many chronic, rare and difficult vulval problems require a multidisciplinary input. A local vulval clinic might be of help in dealing with difficult 
patients and those with unusual skin conditions when expert help is needed. Other members of vulval service might include dermatology, 
genito-urinary medicine, physiotherapy, pain management, psychosexual therapy, pathology and urogynaecology. 
 
Specific vulval conditions 
 
Vulval itching is often the presenting complaint of a vulval skin condition. Itch is a symptom and not a diagnosis. The causes can be separated 
into skin disease (vulval dermatoses), infection and premalignant/malignant disease.  The algorithm outlined in figure 4 is a useful when 
assessing patients. Many of the conditions outlined below require treatment with frequent topical steroids and emollients with a focus on patient 
education and compliance.  The ‘Treatment principles’ section below outlines the general principles of these treatments. 
 
Vulvodynia and vulval intraepithelial neoplasia have been omitted as this these topics were as covered in TOG 2014 and 2011 respectively. 
See table 3 for a summary of the clinical features of specific skin diseases, diagnosis and treatment. 
 
 
 
 
 
Table 3 - summary of the clinical features and treatment of specific skin diseases. 
Diagnosis Clinical appearance Diagnosis Primary treatment Who should manage?
Lichen 
sclerosus 
 
 
Porcelain white papules and plaques 
-Ecchymoses (subcutaneous purpura) 
-Erosions (loss of epidermis) 
-Fissures 
(Late signs- loss of anatomy, fusion, 
adhesions)   
Lichenification (see Fig 5)  
There can be a ‘figure of eight’ 
appearance to the disease. 
Clinically if 
confident or a vulval 
biopsy. Consider 
biopsy if there are 
indurated or 
suspicious areas  
 
 
Superpotent topical steroid 
and emollients (see Topical 
steroids and their use in the 
treatment of vulval skin 
conditions) 
 
Gynaecologist and GP. 
Refer to vulval service 
for treatment resistant 
cases, complications of 
treatment and when 
associated with VIN.  
Lichen planus 
 
‘Classical’ lichen planus - violaceous, 
well demarcated plaques with overlying 
lacy white lines which usually affect the 
labia majora and surrounding skin 
 
Erosive lichen planus -  ‘glazed’ 
erythema or erosions symmetrically 
distributed at vaginal introitus. White 
slightly raised edge to lesions. Lacy 
white lines (Wickham’s striae) in 
surrounding skin. (see Fig 6). May have 
loss of anatomy  
Clinical assessment 
and biopsy from the 
edge of an erosion.  
Lichen planus may 
be seen in the 
mouth or normal 
skin 
Superpotent topical steroid 
and emollients (see Topical 
steroids and their use in the 
treatment of vulval skin 
conditions) 
 
. 
Dermatologist or 
gynaecologist. Refer to 
vulval service for 
treatment resistant 
cases, complications of 
treatment and when 
associated with VIN. 
Erosive lichen planus is 
difficult to treat so refer 
to a vulval service. 
Atopic eczema Symmetrically inflamed, erythematous, 
weepy skin.  No loss of anatomy. May 
be satellite lesions and poorly defined 
edges 
 
Clinical history and 
examination to 
include other skin 
sites for other signs 
of eczema.  
Moderate (e.g clobetasone 
butyrate 0.05%) or potent 
(e.g. Mometasone furoate 
0.1%) topical steroid plus 
emollients to gain control of 
inflammation. 
 
Dermatologist and GP 
Contact 
dermatitis 
Irritant form - Poorly defined erythema 
present where irritant has been applied 
Allergic form – Erythema extends 
outside of area where allergen has been 
applied 
Clinical history and 
examination. 
Patch testing if 
allergic contact 
dermatitis 
suspected 
Moderate (e.g clobetasone 
butyrate 0.05%) or potent 
(e.g. Mometasone furoate 
0.1%) topical steroid plus 
emollients to gain control of 
inflammation. 
Strict avoidance of 
irritants/allergens. 
Dermatologist and GP 
Seborrhoeic 
eczema 
Glazed skin in the intralabial sulci Clinical examination 
of other sites – 
scalp, eyebrows, 
nasolabial folds for 
erythema and fine 
scaling 
Moderate (e.g clobetasone 
butyrate 0.05%) or potent 
(e.g. Mometasone furoate 
0.1%) topical steroid plus 
emollients to gain control of 
inflammation. 
 
Dermatologist and GP 
 
 
Psoriasis 
 
Classically, well demarcated, scaly 
erythematous plaques, but vulval 
psoriatic plaques are smooth, glossy 
and often salmon-pink in colour. Often 
no scale in vulval creases but 
surrounding skin may have typical scaly 
lesions of psoriasis. There is no scarring 
or loss of anatomy (Fig 3). 
Clinical assessment 
to include 
examination of 
‘hidden sites’ for 
other signs of 
psoriasis eg . 
knees, elbows, 
umbilicus, scalp, 
ears, lower back 
and nails Biopsy if 
unsure. 
Moderate potency topical 
steroid plus emollients as 
recommended by NICE 
guidance (7) As the skin 
folds can become particularly 
macerated, there is a chance 
of secondary bacterial or 
fungal infection. A 
combination topical 
preparation (e.g clobetasone 
butyrate 
0.05%/oxytetracycline 
3%/nystatin) may be helpful. 
Dermatologist 
Lichen simplex  
 
 
Lichenification of the skin with erosions 
from chronic scratching. 
Usually no loss of anatomy but can give 
thick ‘leathery’ skin This is often 
superimposed on other itchy skin 
disorders such as eczema and lichen 
sclerosus.  
Clinical history and 
examination. 
 
Superpotent topical steroid 
and emollient. Once control 
of symptoms is achieved, 
moderate potency topical 
steroid may be required 
intermittently. Secondary 
infection with candida or 
bacteria is common and may 
need treatment (2). 
Dermatologist and GP. 
Intertrigo  
(See also 
Flexural rash which may involve the 
groin, natal cleft, submammary region 
and abdominal ‘apron fold’. Common in 
Infection of the 
flexural areas with 
thrush (Candida 
Treatment is usual using 
both oral antibiotics and 
antifungal agents together 
Gynaecologist, 
dermatologist, GP 
vulvovaginal 
candidiasis )  
 
overweight patients.  albicans), 
erythrasma, 
(Corynebacterium 
minutissmum) and 
tinea species 
with the regular use of an 
emollient to improve the skin 
barrier function at this site. 
 
 
Lichen sclerosus 
Lichen sclerosus is an auto-immmune, chronic, inflammatory skin condition that has a predilection for the genital skin in both sexes(Figure 5). 
Early stage disease may be subtle and masked especially if topical steroids have been used prior to referral. 
 
The general management of lichen sclerosus is with topical steroids and emollients and is detailed below (8). There is a small risk of cancer 
(less than 5% risk)(9) so patients should be encouraged to self exam on a regular (suggested monthly) basis to detect skin cancers. Changes 
may include raised lesions irregular lesions, ulceration and persistent eroded areas. Skin fissuring at the posterior fourchette and the initial 
treatment should focus on digital massage of the steroid into the fissure on a daily basis, the encouragement in the use of vaginal dilators and a 
good lubricant. If these measures do not help then consideration should be given to the use of surgical division or refashioning of the fissure or 
skin bridge. 
Lichen planus 
Lichen planus is another autoimmune chronic condition (10).  Two main forms of lichen planus may affect the vulval area. ‘Classical’ lichen 
planus outlined in table 2 is usually very successfully treated with topical steroids and emollients. In contrast, patients with erosive lichen planus 
usually present with pain and burning as erosions occur at the entrance to the vagina and may affect the vaginal mucosal surface. This variant 
leads to considerable scarring and loss of anatomy (Figure 6).  In contrast to the ‘classical’ plaque form of lichen planus this disorder is painful 
rather than itchy and is responds less well to therapy.  Referral to a vulval service is important to optimise disease management. Although the 
evidence is not as clear cut as with lichen sclerosus, there is probably a small chance of malignant potential in lesions of lichen planus (11). 
 
Vulval dermatitis 
The terms dermatitis and eczema are often used interchangeably. There are different types of dermatitis that can affect the vulval area. It is 
important to note that vulval anatomy is normal with eczematous conditions and scarring does not occur. 
Atopic eczema is likely to affect the vulva in conjunction with findings of typical eczema elsewhere. These include poorly defined, symmetrical, 
scaly erythematous areas on the skin creases (especially the antecubital fossae and behind the knees). The skin is often noticeably dry. 
Severe eczema is more widespread over the trunk and limbs. Atopic vulvitis is the commonest cause of vulval itch in children.  
 
Contact dermatitis may be either ‘irritant’ or ‘allergic contact’. Irritant contact dermatitis is particularly common and may be triggered by soaps, 
perfumes, medicaments, urine, faeces and sweat. The barrier function of the skin becomes impaired by local irritants and can subsequently be 
made worse by continued application of the product. Clinical signs of vulval irritant dermatitis include poorly defined intralabial erythema that is 
occurs anywhere where the irritant has been present Small fissures and erosions may be present. Lichenification occurs in longstanding 
disease (12). All of these clinical features are demonstrated in Fig. 2.  It is common that fissures become secondarily infected with skin 
pathogens or candida. It is important to realise this when treatment strategies are implemented. Allergic contact dermatitis is less common; 
around one fifth of patients with vulval skin conditions having a relevant positive patch test result (13). It can be difficult to distinguish from 
irritant contact dermatitis clinically, but affected skin usually extends outside of the genital area in ‘non-contact’ areas. This is because it is an 
immune mediated hypersensitivity reaction. The only way to confidently diagnose allergic contact dermatitis is through patch testing (see 
section on ‘Investigations’) . 
 
Vulval seborrhoeic eczema is difficult to distinguish from psoriasis. It will often manifest as glazed skin in the interlabial sulci bilaterally. Fine 
scale and erythema at other affected body sites such as the nasolabial folds, scalp and eyebrows can aid the diagnosis (14).  
Vulvovaginal candidiasis.  Acute vulval candidiasis is likely to resolve quickly with treatment and patients are unlikely to present to a 
gynaecologist and be managed in primary healthcare. However recurrent candidiasis (more than 6 attacks a year) or chronic infection can be 
more subtle and more recalcitrant to treatment. Patients with an existing vulval condition may develop candidiasis as a secondary problem 
which can be overlooked e.g. a patient with lichen sclerosus treated with topical steroids. There should be a low threshold for taking swabs for 
infection especially those patients who fail to respond to treatment. A suggested treatment regime for recurrent candidiasis includes initial 
treatment followed by a maintenance regime for 6 months (eg Fluconazole 100mg weekly for 6 months). Cessation of therapy may result in 
relapse in at least 50% of women (15) 
 
 
Treatment principles for all vulval disease 
 
There are no core clinical outcome measures for vulval skin disease (16).Suggested clinical outcomes include: 
1) A reduction in symptoms (eg less itch, fewer flare-ups) 
2) An improvement in function (eg sexual function, mobility) 
3) Increased confidence in self management (eg management of flare-ups and self-examination) 
General principles Initial principles of management are the same for all vulval skin conditions and a holistic approach is required. Good 
education, support and counselling are required with extra time given to address the disease process, discussing general vulval care measures 
and managing patient expectation (2). It is useful to provide information leaflets, direct patients to relevant patient-oriented websites and write 
down instructions for applying topical agents (see ‘Additional resources’ for sources of patient information). The use of a mirror or model in the 
clinic setting is helpful to show patients where to apply their topical treatments. 
 
Correct barrier function The goal of therapy is to correct barrier function and reduce inflammation. For washing, soap and other routine cleaning 
agents (e.g. wipes) should be avoided, as they are likely to act as irritants and sensitising allergens. Irritation from urinary and faecal 
incontinence need to be addressed as these will be a common cause of irritant vulvitis and make underlying skin pathology worse. ‘Soap 
substitution’ with a bland cream or ointment based emollient is best for cleansing. The same agent can then be used as an emollient to both 
provide a barrier to the site and sooth inflamed skin. There is no preferred emollient to use and some can cause irritation. Emollient creams (not 
ointments) can be placed in the fridge. Patients find this soothing and lowering skin temperature is thought to reduce itch through central 
inhibitory pathways (17).  
 
Topical steroids and their use in the treatment of vulval skin conditions 
Inflammation reduction associated with skin disease (such as in lichen planus, lichen sclerosus and eczema) is achieved by the use of topical 
steroids. Topical steroids are often ineffectively used in the vulval area due to concerns from patients and non-specialists about side-effects, 
particularly skin or mucosal atrophy.  It is important therefore to use the correct strength of steroid for the necessary length of time on the 
appropriate body site. Mucosal surfaces such as the vulval vestibule are remarkably resistant to steroid atrophy.  
 
In contrast, keratinised surfaces such as the labiocrural folds, perineum, perianal area and thighs can develop skin thinning and striae (stretch 
marks) with inappropriate use with potent topical steroids (2). Overusage of topical steroids appears as thinned skin which appears redder and 
is reversible in the early stages. In the later stages permanent telangiectasia and striae can develop.  Topical calcineurin inhibitors in the vulval 
region reduce inflammation and do not cause skin atrophy. However their role is not fully understood and there is a theoretical risk of long term 
localised immunosuppression from these agents causing skin cancers (18). 
In lichen sclerosus and lichen planus, the use of superpotent topical steroids is recommended as first-line therapy. Cochrane systematic 
reviews of interventions for both lichen sclerosus and lichen planus (19,20) have been published. There is reasonable randomised controlled 
trial evidence for the use of topical steroids in lichen sclerosus and The British Association of Dermatologists suggest the use of the 
superpotent topical steroid, clobetasol proprionate 0.05%, over a three-month reducing course (8). There are currently no specific guidelines for 
lichen planus; standard practice is to use a similar regimen as for lichen sclerosus and case series evidence supports this (21,22).  
 
 
In general topical steroids should be used once-daily. There is no evidence to suggest that twice-daily application is superior, although twice-
daily has greater potential to cause side effects (23). Ointments are preferable to creams as they contain fewer constituents and therefore have 
a lower chance of causing irritation/contact allergy. Once control of inflammation and symptoms has been achieved, topical steroids should be 
reduced to the minimum frequency required to maintain remission. The concept of ‘weekend therapy’, that is, applying topical steroids on two 
consecutive days per week, is effective in atopic eczema patients (24) and can extrapolated to chronic vulval diseases such as lichen sclerosus 
and lichen planus where long-term maintenance therapy is required. A patient with these conditions will use approximately 30-60 g of topical 
steroid per year as maintenance therapy (8). Topical steroids should only be used on affected areas to prevent side-effects in adjacent skin.. 
Failure to respond to treatment If a patient fails to respond to appropriate treatment the following should be considered: 
1. Poor adherence to prescribed treatment regimen – ‘steroid phobia’ is a well recognised problem when treating skin conditions. Many 
healthcare professionals, including pharmacists, will compound the issue by advising the patient to use sparingly and recommending 
not to use on ‘sensitive areas’. This cautious approach can be detrimental to the patient’s treatment plan. The patient should be advised 
to apply the topical steroid in terms of the finger tip unit (A finger tip is from the very end of the finger to the first crease in the finger. It 
does NOT mean a blob on the fingertip). The number of fingertip units required is usually one to two but is specifically tailored to the 
patient depending upon surface area affected by the condition (25). 
2. Inaccurate placement of topical steroid – the patient may be applying the topical treatment to an unaffected area. Especially common if 
the patient is elderly and unable to use a mirror to see what they are doing. In clinic the exact location of application should be 
explained, diagrams/photographs or models can be used as an aid. 
3. Continued exposure to irritants – urine or faeces, external products such as wipes or non prescribed topical treatments and over 
washing with water can all contribute towards irritation and ongoing symptoms. 
4. Incorrect diagnosis – if adherence and skin care practices are assessed as adequate, it may be that the diagnosis given is incorrect. An 
allergic contact dermatitis to topical treatments may have occurred (see section on Patch Testing) or there may be pre-malignant or 
malignant change in the affected area. If there is any concern a biopsy should be taken. 
 
 
Conclusion 
Vulval skin conditions are common and generally easy to diagnose by an accurate history and examination. Sometimes further investigations 
such as vulval swabs, patch-tests and biopsies are needed. For patients with unusual clinical features, or who fail to respond to adequate 
therapy, pre-malignancy or malignancy should be considered as an alternative diagnosis. Complex, rare and treatment resistant patients 
should be referred to a vulval service. 
 
Further information is available on line from the following resources; 
Dermnetnz: The Dermatology Resource www.dermnetnz.org 
British Society for the Study of Vulval Disease www.bssvd.org 
International Society for the study of Vulvovaginal Disease www.issvd.org 
Clinical Knowledge Summaries www.cks.nhs.uk 
  
 
 
FIGURES 
Figure 1: Schematic representation of the normal adult vulva. Copyright  “Dawn Danby and Paul Waggoner”, c/o ISSVD 
Figure 2: Contact dermatitis affecting the female genitalia. Note poorly defined erythema of the genitocrural skin, erosions due to excoriation in 
the inflamed skin and white thickening (lichenification) of the labia majora due to scratching. 
Figure 3: Psoriasis affecting the female genitalia. Well demarcated erythema surrounding the anogenital area with typical psoriatic plaques in 
surrounding skin. The genital plaque has typical scale in the perianal area, but lack of scale in the perineal and vulval areas. 
Figure 4– algorithm for the management of vulval itching 
Figure 5: Advanced vulval lichen sclerosus. Whiteness, loss of anatomy, ecchymosis seen on the left labia, scarring over the clitoral hood 
Figure 6: Erosive lichen planus. Well demarcated symmetrical erosions present at the vaginal introitus. Note anatomical changes with loss of 
the labia minora and clitoral hood, anterior fusion and narrowing of the vaginal opening. 
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 Figure 5: Advanced vulval lichen sclerosus. Whiteness, loss of anatomy, ecchymosis seen on the left labia, scarring over the clitoral hood 
 
Figure 6: Erosive lichen planus. Well demarcated symmetrical erosions present at the vaginal introitus. Note anatomical changes with loss of the labia minora and clitoral hood, 
anterior fusion and narrowing of the vaginal opening. 
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25 CPD questions True False 
 
The following conditions should ideally be managed within specialist care (vulval clinic). 
 
Lichen sclerosus follow-up 
F – follow-up can be with GPs or general gynaecology/dermatology clinics 
  
Unifocal vulval intraepithelial neoplasia 
F – can be managed by general gynaecologists 
 
Vulvodynia 
T – treatment resistant vulvodynia should be referred to the vulval service but all general gynaecolgogists should be able to start basic 
treatment 
 
Bullous disease 
T – a rare, complex condition 
 
With regards vulval disease management 
 
Creams have better moisturizing properties than ointments 
F 
 
With an ulcerated vulval lesion, a punch biopsy should be taken from the central area of the lesion as this represents the most useful site for 
diagnosis. 
F – Biopsies should be taken from the edge of the lesion at the junction of the normal skin and the lesion. Areas of inflammation are often 
histologically non specific. 
In the absence of a diagnosis, mapping vulval biopsies should be taken in symptomatic patients even if the skin looks normal. 
F – biopsying clinically normal skin should be discouraged as there is little additional diagnostic benefit. Normal skin biopsy reports are often 
reported as showing ‘inflammation’ which can lead to inappropriate prescription of topical steroids. 
 
Regarding inflammatory vulval skin conditions 
 
First line treatment with topical steroids for vulval lichen sclerosus and erosive lichen planus should be reducing potency regime for three 
months 
F – Superpotent topical steroids should be used in with reducing frequency 
 
Vulval psoriasis should be treated with a superpotent toptical steroid 
F – NICE guidance recommends that moderate potency topical steroids are used 
 
Side effects from topical steroid use are uncommon 
T – If an appropriate strength and frequency of topical steroid are used, side effects such as atrophy and striae are uncommon.  
 
Dermatologist patch testing should be considered for all patients with recurrent vulval itching 
F – only for those patients where allergic contact dermatitis require exclusion 
 
Biopsy is always required to diagnose lichen sclerosus 
F – Biopsy is required if the diagnosis is unclear, there has been poor response to standard treatment, or if there are indurated or suspicious 
areas on clinical examination  
 
Erosive lichen planus presents with pain rather than itch 
T – Erosive lichen planus is usually painful due to mucosal erosion. Classical lichen planus is itchy 
 
The risk of squamous cell carcinoma development in lichen sclerosus is 10% 
F – less than 5% 
 
 
With regards skin lesion morphology 
 
A papule is a small palpable lesion less than 0.5cm in diameter 
T 
 
An ulcer is a shallow denuded area due to loss of the epidermis (surface layer of skin) 
F – this is an erosion 
 
Patients with vulval skin lichenification usually have painful, thickened skin in the area scratching 
F – pruritus is usually the main symptom. Secondary pain may be present if the skin is broken through scratching 
 
A vesicle is a small fluid filled blister less than 0.5cm diameter 
T 
 
Vulval intraepithelial neoplasia is commonly plaque-like 
T 
 
With regards topical steroids in the management of vulval lichen sclerosus 
 
Follow-up treatment is usually with daily treatment of superpotent topical steroid ointments in patients who are in remission 
F – usually treatment is twice a week, but this can be increased depending on symptoms 
 
Twice a day treatment is more likely than once a day treatment to produce remission of symptoms 
F – once a day treatment frequently produces good symptom control 
 
May predispose a patient to secondary candida infection 
T 
 
Will reverse anatomical change in advanced disease 
F – skin texture will improve but the anatomical loss will not reverse 
 
May cause allergic contact dermatitis 
T – this may occur when on treatment 
 
 
 
 
 
 
